(Q37532641)

20 August 2017

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial (English)

1 reference

20 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Luboš Petruželka

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Igor N. Bondarenko

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Rustem Khasanov

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Luca Malorni

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Miguel Martin

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Guy Jerusalem

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Roberto Torres

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Didier Verhoeven

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

José L Pedrini

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Iya Smirnova

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Mikhail R Lichinitser

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Kelly Pendergrass

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sally Garnett

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Yuri Rukazenkov

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

7 December 2013

1 reference

Journal of the National Cancer Institute

20 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

djt337

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

Combination anastrozole and fulvestrant in metastatic breast cancer

10 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

Clinical review: Effect of endocrine therapies on bone in breast cancer patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

Fulvestrant (Faslodex) -- how to make a good drug better

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906991

FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer

1 September 2018

1 reference

12 December 2020

Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven

1 reference

12 December 2020

Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer

1 reference

12 December 2020

Tamoxifen and the uterus and endometrium

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJT337

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

PubMed publication ID

24317176

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24317176%20AND%20SRC:MED&resulttype=core&format=json